Human amnion-derived mesenchymal stem cells promote osteogenic and angiogenic differentiation of human adipose-derived stem cells.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Cell Differentiation*/genetics ; Neovascularization, Physiologic*/genetics ; Osteogenesis*/genetics; Adipose Tissue/*cytology ; Amnion/*cytology ; Mesenchymal Stem Cells/*cytology; Alkaline Phosphatase/metabolism ; Biomarkers/metabolism ; Calcification, Physiologic/genetics ; Cells, Cultured ; Extracellular Matrix/metabolism ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Gene Expression Regulation ; Humans ; Mesenchymal Stem Cells/metabolism ; Phosphorylation

Tissue engineering using suitable mesenchymal stem cells (MSCs) shows great potential to regenerate bone defects. Our previous studies have indicated that human amnion-derived mesenchymal stem cells (HAMSCs) could promote the osteogenic differentiation of human bone marrow mesenchymal stem cells (HBMSCs). Human adipose-derived stem cells (HASCs), obtained from adipose tissue in abundance, are capable of multi-lineage differentiation. In this study, the effects of HAMSCs on osteogenic and angiogenic differentiation of HASCs were systematically investigated. Proliferation levels were measured by flow cytometry. Osteoblastic differentiation and mineralization were investigated using chromogenic alkaline phosphatase activity (ALP) activity substrate assays, Alizarin red S staining, real-time polymerase chain reaction (real-time PCR) analysis of osteogenic marker expression, and Western blotting. We found that HAMSCs increased the proliferation and osteoblastic differentiation of HASCs. Moreover, enzyme-linked immunosorbent assay (ELISA) and human umbilical vein endothelial cells (HUVECs) tube formation suggested HAMSCs enhanced angiogenic potential of HASCs via secretion of increased vascular endothelial growth factor (VEGF). Thus, we conclude that HAMSC might be a valuable therapeutic approach to promote HASCs-involved bone regeneration.

J Biol Chem. 2004 Oct 8;279(41):42709-18. (PMID: 15304489)
J Cell Biochem. 2006 Dec 1;99(5):1233-9. (PMID: 16795049)
Cardiovasc Res. 2012 Mar 1;93(3):525-34. (PMID: 22155484)
J Cell Mol Med. 2014 Jun;18(6):1028-34. (PMID: 24708439)
Stem Cell Res Ther. 2011 Jul 28;2(4):33. (PMID: 21861868)
Acta Biochim Pol. 2003;50(4):1019-38. (PMID: 14739992)
Tissue Eng Part A. 2009 Nov;15(11):3487-97. (PMID: 19438323)
Curr Pharm Des. 2009;15(24):2784-90. (PMID: 19689349)
Tunis Med. 2006 Nov;84(11):751-7. (PMID: 17294906)
Tissue Eng Part A. 2010 Jan;16(1):101-14. (PMID: 19642855)
Mol Biol Cell. 2002 Dec;13(12):4279-95. (PMID: 12475952)
ACS Appl Mater Interfaces. 2014 Dec 24;6(24):22602-11. (PMID: 25478703)
Nat Biotechnol. 2000 Sep;18(9):959-63. (PMID: 10973216)
Stem Cells Dev. 2012 May 20;21(8):1309-20. (PMID: 21762016)
Expert Rev Med Devices. 2005 May;2(3):303-17. (PMID: 16288594)
Drug Discov Today. 2003 Nov 1;8(21):980-9. (PMID: 14643161)
Angiogenesis. 2014 Oct;17(4):921-33. (PMID: 25086616)
J Bone Miner Res. 2006 Apr;21(4):637-46. (PMID: 16598384)
Biochem Biophys Res Commun. 2011 May 27;409(1):82-9. (PMID: 21565172)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
World J Stem Cells. 2014 Jul 26;6(3):312-21. (PMID: 25126381)
Tissue Eng Part A. 2009 Apr;15(4):945-56. (PMID: 18788981)
Iran J Basic Med Sci. 2016 Feb;19(2):145-53. (PMID: 27081458)
Life Sci. 2015 Jun 15;131:37-43. (PMID: 25896660)
PLoS One. 2015 May 06;10 (5):e0125387. (PMID: 25946081)
Tissue Eng Part A. 2010 Sep;16(9):2953-66. (PMID: 20486792)
Indian J Dent Res. 2009 Jan-Mar;20(1):7-12. (PMID: 19336852)
Stem Cells Int. 2016;2016:4851081. (PMID: 26697075)
Biomed Res Int. 2015;2015:324014. (PMID: 26491665)
Int J Mol Sci. 2015 May 07;16(5):10491-506. (PMID: 25961955)
J Biol Chem. 2000 Feb 18;275(7):5037-42. (PMID: 10671545)
Tissue Eng. 2001 Apr;7(2):211-28. (PMID: 11304456)
BMC Dev Biol. 2007 Feb 21;7:11. (PMID: 17313666)
Mol Cells. 2016 Mar;39(3):186-94. (PMID: 26743906)
Colloids Surf B Biointerfaces. 2014 Oct 1;122:719-728. (PMID: 25179112)
J Periodontol. 2007 Oct;78(10):2036-42. (PMID: 18062126)
J Mol Histol. 2015 Feb;46(1):13-20. (PMID: 25432786)
Circ Res. 2007 May 11;100(9):1249-60. (PMID: 17495232)
Stem Cells Dev. 2013 Apr 15;22(8):1275-87. (PMID: 23211052)
Adv Med Sci. 2013;58(2):185-95. (PMID: 24327530)
Proteomics. 2006 Feb;6(4):1166-74. (PMID: 16421932)
PLoS One. 2011 Feb 04;6(2):e16789. (PMID: 21326862)
Tissue Eng Part B Rev. 2011 Jun;17(3):195-211. (PMID: 21338267)
J Tissue Eng Regen Med. 2007 Jul-Aug;1(4):296-305. (PMID: 18038420)
Tissue Eng Part A. 2014 Dec;20(23-24):3303-13. (PMID: 24568547)
Growth Factors. 2010 Oct;28(5):306-17. (PMID: 20497064)
Tissue Eng. 2003 Aug;9(4):733-44. (PMID: 13678450)
Curr Pharm Des. 2013;19(13):2459-73. (PMID: 23278600)
Sci Rep. 2016 Feb 25;6:22005. (PMID: 26911441)
J Periodontol. 2007 Jan;78(1):47-51. (PMID: 17199538)
J Nippon Med Sch. 2009 Apr;76(2):56-66. (PMID: 19443990)
Stem Cells Dev. 2012 Aug 10;21(12):2189-203. (PMID: 22188562)
Biomaterials. 2011 Jan;32(3):760-8. (PMID: 20947160)
J Periodontol. 2009 Nov;80(11):1815-23. (PMID: 19905951)
Phytother Res. 2017 May;31(5):792-800. (PMID: 28337797)
Cell Tissue Res. 2005 Feb;319(2):243-53. (PMID: 15654654)
FASEB J. 2009 Aug;23(8):2772-9. (PMID: 19346294)
J Biosci Bioeng. 2009 Dec;108(6):530-7. (PMID: 19914589)
Eur Cell Mater. 2008 May 02;15:100-14. (PMID: 18454418)
Biomaterials. 2009 May;30(13):2489-98. (PMID: 19147220)
Macromol Biosci. 2010 Jan 11;10(1):12-27. (PMID: 19688722)
Bone. 2009 Sep;45(3):517-27. (PMID: 19505603)
Expert Rev Mol Med. 2014 May 09;16:e9. (PMID: 24810570)

0 (Biomarkers)
EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
EC 3.1.3.1 (Alkaline Phosphatase)

Date Created: 20171012 Date Completed: 20171020 Latest Revision: 20181202

20240829

PMC5636128

10.1371/journal.pone.0186253

29020045